← vista completa

Publicado el 1 de marzo de 2004 | http://doi.org/10.5867/medwave.2004.02.2355

Novedades sobre virus respiratorio sincicial

Update on respiratory syncytial virus

Daniela Valdivia

Esta obra de Medwave está bajo una licencia Creative Commons Atribución-NoComercial 3.0 Unported. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Autores

Daniela Valdivia

Figures

Article has no figures.

Foro

No hay mensajes

Historial

Citación Valdivia D. Update on respiratory syncytial virus. Medwave 2004;4(02):e2355 doi: 10.5867/medwave.2004.02.2355

Envío 01/01/1970

Aceptación 01/01/1970

Publicación 01/03/2004

Indice

Métricas

Vistas en HTML

150

Descargas en PDF

15

Total

165

% Descargas en PDF

10%

Ver detalle

Notas

Referencias

  1. Meissner HC, Welliver RC, Chartrand SA, Law BJ, Weisman LE, Dorkin HL, et al. Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion. Pediatr Infect Dis J. 1999 Mar;18(3):223-31. | CrossRef | PubMed
  2. Halasa NB, Williams JV, Wilson GJ, Walsh WF, Schaffner W, Wright PF. Medical and economic impact of a respiratory syncytial virus outbreak in a neonatal intensive care unit. Pediatr Infect Dis J. 2005 Dec;24(12):1040-4. | CrossRef | PubMed
  3. Meissner HC, Fulton DR, Groothuis JR, Geggel RL, Marx GR, Hemming VG,et al. Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin. Antimicrob Agents Chemother. 1993 Aug;37(8):1655-8. | CrossRef | PubMed
  4. Sánchez PJ. Immunoprophylaxis for respiratory syncytial virus. Pediatr Infect Dis J. 2002 May;21(5):473-8. | CrossRef | PubMed
  5. Romero JR. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage. Pediatr Infect Dis J. 2003 Feb;22(2 Suppl):S46-54. | CrossRef | PubMed
  6. Prais D, Schonfeld T, Amir J; Israeli Respiratory Syncytial Virus Monitoring Group. Admission to the intensive care unit for respiratory syncytial virus bronchiolitis: a national survey before palivizumab use. Pediatrics. 2003 Sep;112(3 Pt 1):548-52. | CrossRef | PubMed
  7. Piedra PA. Clinical experience with respiratory syncytial virus vaccines. Pediatr Infect Dis J. 2003 Feb;22(2 Suppl):S94-9. | CrossRef | PubMed
  8. Mohapatra SS. Mucosal gene expression vaccine: a novel vaccine strategy for respiratory syncytial virus. Pediatr Infect Dis J. 2003 Feb;22(2 Suppl):S100-3; discussion S103-4. | PubMed
  9. Groothuis JR, Woodin KA, Katz R, Robertson AD, McBride JT, Hall CB, et al. Early ribavirin treatment of respiratory syncytial viral infection in high-risk children. J Pediatr. 1990 Nov;117(5):792-8. | CrossRef | PubMed
  10. Gensheimer KF, Meltzer MI, Postema AS, Strikas RA. Influenza pandemic preparedness. Emerg Infect Dis. Emerg Infect Dis. 2003 Dec;9(12):1645-8. | CrossRef | PubMed